Does Post-Void Residual Urine Volume Affect Potential Recurrence Risk for Non-Muscle Invasive Bladder cancer?

References

• DiPierro GB , GuliaC , CristiniCet al.Bladder cancer: a simple model becomes complex. Curr. Genom.13(5), 395–415 (2012).
   PubMed Web of Science ®Google Scholar
• MatulewiczRS , SteinbergGD. Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev. Urol.22(2), 43–51 (2020).
   PubMedGoogle Scholar
• Van RhijnBWG , BurgerM , LotanYet al.Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur. Urol.56(3), 430–442 (2009).
   PubMed Web of Science ®Google Scholar
• CassellA , YunusaB , JallohMet al.Non-muscle invasive bladder cancer: a review of the current trend in Africa. World J. Oncol.10(3), 123–131 (2019).
   PubMedGoogle Scholar
• IsharwalS , KonetyB. Non-muscle invasive bladder cancer risk stratification. Indian J. Urol.31(4), 289–296 (2015).
   PubMedGoogle Scholar
• GulA , CulhaM , CakirO. Post-void residual urine volume: potential recurrence risk factor for bladder cancer among the male smoker patients. Eastern J. Med.23, 280–283 (2018).
   Google Scholar
• ShoreND , PalouRedorta J , RobertGet al.Non-muscle-invasive bladder cancer: an overview of potential new treatment options. Urologic Oncol.39(10), 642–663 (2021).
   PubMed Web of Science ®Google Scholar
• TokuyamaN , SaitoA , MuraokaRet al.Prediction of non-muscle invasive bladder cancer recurrence using machine learning of quantitative nuclear features. Mod. Pathol.35(4), 533–538 (2022).
   PubMed Web of Science ®Google Scholar
• ZachosI , TzortzisV , KonstantinopoulosPAet al.Molecular pathogenesis of non muscle-invasive bladder cancer: implications for novel targeted therapies. Curr. Mol. Med.11(8), 623–632 (2011).
   PubMed Web of Science ®Google Scholar
• AbramsP , ChappleC , KhouryS , RoehrbornC , DeLa Rosette J. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol181(4), 1779–1787 (2009).
   PubMed Web of Science ®Google Scholar
• KellyCE. Evaluation of voiding dysfunction and measurement of bladder volume. Rev. Urol.6(Suppl. 1), S32–S37 (2004).
   PubMedGoogle Scholar
• SazukaT , SakamotoS , ImamuraYet al.Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma. International J. Urol.27(11), 1024–1030 (2020).
   PubMed Web of Science ®Google Scholar
• HeneyNM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urologic Clinics of North America19(3), 429–433 (1992).
   PubMed Web of Science ®Google Scholar
• GreggJR , DahmP , ChangSS. Guideline-based management of non-muscle invasive bladder cancer. Indian J. Urol.31(4), 320–326 (2015).
   PubMedGoogle Scholar
• JonesJ , LarchianW. Non-muscle-invasive bladder cancer (Ta, T1, and CIS). Campbell-Walsh Urol.3, 2335–2354 (2012).
   Google Scholar
• AminMB , GreeneFL , EdgeSBet al.The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin.67(2), 93–99 (2017).
   PubMed Web of Science ®Google Scholar
• MirMC , CampiR , LoriotYet al.Adjuvant systemic therapy for high-risk muscle-invasive bladder cancer after radical cystectomy: current options and future opportunities. European Urol. Oncol. doi:10.1016/j.euo.2021.04.004 (2021).
   Web of Science ®Google Scholar
• YoshidaT , KatesM , FujitaK , BivalacquaTJ , McconkeyDJ. Predictive biomarkers for drug response in bladder cancer. International J. Urol.26(11), 1044–1053 (2019).
   PubMed Web of Science ®Google Scholar
• GroenendijkFH , DeJong J , FransenVan De Putte EEet al.ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur. Urol.69(3), 384–388 (2016).
   PubMed Web of Science ®Google Scholar
• YangZ , ZhangR , GeYet al.Somatic FGFR3 mutations distinguish a subgroup of muscle-invasive bladder cancers with response to neoadjuvant chemotherapy. EBioMedicine35, 198–203 (2018).
   PubMed Web of Science ®Google Scholar
• ChoudhuryNJ , CampanileA , AnticTet al.Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J. Clinical Oncol.34(18), 2165–2171 (2016).
   PubMed Web of Science ®Google Scholar
• García-CasasA , García-OlmoDC , García-OlmoDJWJOCO. Further the liquid biopsy: gathering pieces of the puzzle of genometastasis theory. World J. Clin. Oncol.8(5), 378 (2017).
   PubMedGoogle Scholar
• Contreras-SanzA , RobertsME , SeilerR , BlackPC. Recent progress with next-generation biomarkers in muscle-invasive bladder cancer. International J. Urol.24(1), 7–15 (2017).
   PubMed Web of Science ®Google Scholar
• DeKruijff IE , BeijeN , MartensJWM , DeWit R , BoormansJL , SleijferS. Liquid biopsies to select patients for perioperative chemotherapy in muscle-invasive bladder cancer: a systematic review. European Urol. Oncol.4(2), 204–214 (2021).
   PubMed Web of Science ®Google Scholar
• CameronAP , Lewicky-GauppC , SmithARet al.Baseline lower urinary tract symptoms in patients enrolled in LURN: a prospective, observational cohort study. J. Urol.199(4), 1023–1031 (2018).
   PubMed Web of Science ®Google Scholar
• Bani-HaniM , AbdelMajid A , Al-ZubiMTet al.Continuous saline bladder irrigation in reducing recurrence and progression when compared to immediate mitomycin-C instillation post-resection of bladder tumor: a short communication. Asian Pac. J. Cancer Prev.23(1), 171–175 (2022).
   PubMedGoogle Scholar
• SazukaT , SakamotoS , NakamuraKet al.Impact of post-void residual urine volume on intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. International J. Urol.26(12), 1106–1112 (2019).
   PubMed Web of Science ®Google Scholar